{"disease":{"id":"mss","name":"mss"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07186894","title":"Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05669430","title":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"GV20 Therapeutics","has_results":false},{"nct_id":"NCT07070518","title":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"GV20 Therapeutics","has_results":false},{"nct_id":"NCT03207867","title":"A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":315,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07500038","title":"Evidence-Based Practice for the Management of Musculoskeletal Symptoms in Breast Cancer Patients Undergoing Endocrine Therapy: A Multicultural Perspective","phase":"NA","overall_status":"COMPLETED","enrollment_count":289,"lead_sponsor_name":"Yuling CAO","has_results":false},{"nct_id":"NCT06849362","title":"Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"Yue Gou","has_results":false},{"nct_id":"NCT06794099","title":"Study on the Applicability of CCR Criteria in Rectal Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT06791512","title":"mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":166,"lead_sponsor_name":"Jun Huang","has_results":false},{"nct_id":"NCT06959667","title":"Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":144,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03549000","title":"A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07405736","title":"Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":124,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04354246","title":"COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Compugen Ltd","has_results":false},{"nct_id":"NCT04046445","title":"Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":96,"lead_sponsor_name":"Amal Therapeutics","has_results":false},{"nct_id":"NCT07005570","title":"Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":86,"lead_sponsor_name":"Dechang Diao","has_results":false},{"nct_id":"NCT03271047","title":"Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04432857","title":"AN0025 and Pembrolizumab Combination in Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":63,"lead_sponsor_name":"Adlai Nortye Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT06321081","title":"ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Beijing Hospital","has_results":false},{"nct_id":"NCT07446322","title":"FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Oncolytics Biotech","has_results":false},{"nct_id":"NCT06930118","title":"The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT03642067","title":"Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT05877573","title":"Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":53,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT04483219","title":"Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":53,"lead_sponsor_name":"China Medical University, China","has_results":false},{"nct_id":"NCT04659382","title":"Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Federation Francophone de Cancerologie Digestive","has_results":false},{"nct_id":"NCT04527068","title":"QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06549907","title":"A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05731726","title":"Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06908031","title":"SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":49,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT03711058","title":"Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT06199232","title":"Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":47,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT05933980","title":"Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":44,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07446465","title":"FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Ye Xu","has_results":false},{"nct_id":"NCT06415851","title":"Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Zhangfa Song","has_results":false},{"nct_id":"NCT06593548","title":"Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06239870","title":"Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"Yunnan Cancer Hospital","has_results":false},{"nct_id":"NCT06936488","title":"A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":35,"lead_sponsor_name":"Huai'an First People's Hospital","has_results":false},{"nct_id":"NCT03892798","title":"Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene","phase":"","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT05216653","title":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false},{"nct_id":"NCT06613113","title":"Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Ningbo Medical Center Lihuili Hospital","has_results":false},{"nct_id":"NCT03665077","title":"Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome","phase":"NA","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT04030260","title":"Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":28,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06992024","title":"Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07156682","title":"QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":21,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT03274804","title":"Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University Hospital Heidelberg","has_results":true},{"nct_id":"NCT06513624","title":"ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"National University Hospital, Singapore","has_results":false},{"nct_id":"NCT04098068","title":"Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT05019534","title":"Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT07510308","title":"Clinical Study of MSH2-/- Tumor Cell Vaccines for Advanced pMMR Colorectal Cancer Patients","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":9,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT05733611","title":"RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Replimune, Inc.","has_results":false}],"total":48},"guidelines":[],"source":"Drug Landscape verified database"}